for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

NuVasive, Inc.

NUVA.OQ

Latest Trade

52.31USD

Change

0.63(+1.22%)

Volume

58,378

Today's Range

51.15

 - 

52.32

52 Week Range

28.55

 - 

81.91

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
51.68
Open
51.41
Volume
58,378
3M AVG Volume
20.06
Today's High
52.32
Today's Low
51.15
52 Week High
81.91
52 Week Low
28.55
Shares Out (MIL)
51.25
Market Cap (MIL)
2,648.74
Forward P/E
63.33
Dividend (Yield %)
--

Next Event

NuVasive Inc Extraordinary Shareholders Meeting

Latest Developments

More

Nuvasive Announces Second Quarter 2020 Financial Results

Nuvasive Announces Certain Preliminary Unaudited Second Quarter 2020 Results

Nuvasive Says Anticipate Q2 Net Sales To Be Greater Than 55% Of Q2 2019 Net Sales

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About NuVasive, Inc.

Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.

Industry

Medical Equipment & Supplies

Contact Info

7475 Lusk Blvd

SAN DIEGO, CA

92121-5707

United States

+1.858.9091800

https://www.nuvasive.com/

Executive Leadership

Gregory T. Lucier

Chairman of the Board

Matthew W. Link

President

J. Christopher Barry

Chief Executive Officer, Director

Matthew K. Harbaugh

Executive Vice President, Chief Financial Officer

Lucas Vitale

Chief Human Resource Officer

Key Stats

2.39 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

1.0K

2018

1.1K

2019

1.2K

2020(E)

1.0K
EPS (USD)

2017

1.910

2018

2.230

2019

2.470

2020(E)

0.974
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.49
Price To Book (MRQ)
2.96
Price To Cash Flow (TTM)
19.72
Total Debt To Equity (MRQ)
154.47
LT Debt To Equity (MRQ)
83.61
Return on Investment (TTM)
-0.22
Return on Equity (TTM)
-0.17

Latest News

Latest News

BRIEF-Nuvasive Says Anticipate Q2 Net Sales To Be Greater Than 55% Of Q2 2019 Net Sales

* NUVASIVE SAYS ANTICIPATE Q2 NET SALES TO BE GREATER THAN 55% OF Q2 2019 NET SALES, SUBJECT TO STABILITY IN JUNE - PRESENTATION

BRIEF-NuVasive Announces Full Exercise Of Option By Initial Purchasers To Purchase Additional 1.00% Convertible Senior Notes Due 2023

* NUVASIVE, INC. ANNOUNCES FULL EXERCISE OF OPTION BY INITIAL PURCHASERS TO PURCHASE ADDITIONAL 1.00% CONVERTIBLE SENIOR NOTES DUE 2023 Source text for Eikon: Further company coverage:

BRIEF-Nuvasive Announces Pricing Of Offering Of $400 Million Of 1.00% Convertible Senior Notes Due 2023

* NUVASIVE, INC. ANNOUNCES PRICING OF OFFERING OF $400 MILLION OF 1.00% CONVERTIBLE SENIOR NOTES DUE 2023 Source text for Eikon: Further company coverage:

BRIEF-NuVasive Announces Proposed Offering Of $400 Mln Of Convertible Senior Notes Due 2023

* NUVASIVE, INC. ANNOUNCES PROPOSED OFFERING OF $400 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2023 Source text for Eikon: Further company coverage:

BRIEF-Nuvasive Implements Compensation Reductions For Board Of Directors

* IMPLEMENTING COMPENSATION REDUCTIONS FOR ITS BOARD OF DIRECTORS AND EXECUTIVE OFFICERS

BRIEF-Randomized Controlled Trial Results Published In 'Spine' Demonstrate Efficacy Of Nuvasive Attrax Putty In Posterolateral Lumbar Fusion

* RANDOMIZED CONTROLLED TRIAL RESULTS PUBLISHED IN 'SPINE' DEMONSTRATE EFFICACY OF NUVASIVE ATTRAX® PUTTY IN POSTEROLATERAL LUMBAR FUSION Source text for Eikon: Further company coverage:

BRIEF-Nuvasive Inc Says On February 24, Entered Into A Second Amended And Restated Credit Agreement

* NUVASIVE INC - ON FEBRUARY 24, ENTERED INTO A SECOND AMENDED AND RESTATED CREDIT AGREEMENT

BRIEF-NuVasive Inc Announces Proposed Offering Of $450 Million Of Convertible Senior Notes Due 2025

* NUVASIVE, INC. ANNOUNCES PROPOSED OFFERING OF $450 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2025 Source text for Eikon: Further company coverage:

BRIEF-Nuvasive Says Q4 Revenue Rose 7.6 Percent To $310.4 Million

* NUVASIVE ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

Smith & Nephew in talks to buy NuVasive for over $3 billion: FT

Britain's Smith & Nephew Plc has held talks to buy U.S. medical equipment maker NuVasive in a deal that would be worth more than $3 billion, the Financial Times reported on Friday, citing people familiar with the talks.

UPDATE 1-Smith & Nephew in talks to buy NuVasive for over $3 bln - FT

Britain's Smith & Nephew Plc has held talks to buy U.S.-based medical equipment maker NuVasive in a deal that would be worth more than $3 billion, the Financial Times reported on Friday, citing people familiar with the talks.

Smith & Nephew in talks to buy NuVasive for over $3 bln - FT

Britain's Smith & Nephew Plc has held talks to buy U.S.-based medical equipment maker NuVasive in a deal that would be worth more than $3 billion, the Financial Times reported on Friday, citing people familiar with the talks.

BRIEF-NuVasive Reports Q1 GAAP Loss Per Share Of $0.53

* FY2018 REVENUE VIEW $1.10 BILLION -- THOMSON REUTERS I/B/E/S

BRIEF-Nuvasive Posts Q4 Adj. Earnings Per Share $0.56

* NUVASIVE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-John DeFord To Join NuVasive Board Of Directors

* NUVASIVE INC - AS A RESULT OF DEFORD'S APPOINTMENT, NUVASIVE BOARD OF DIRECTORS CONSISTS OF 10 DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-NuVasive Comments On Expected Impact Of U.S. Tax Reform

* NUVASIVE INC - SAVINGS FROM TAX REFORM EXPECTED TO BOOST FORWARD-LOOKING FREE CASH FLOW, NON-GAAP EPS IN EXCESS OF 10 % PER YEAR BEGINNING IN 2018

BRIEF-Nuvasive To Acquire Safepassage

* NUVASIVE INC - NUVASIVE EXPECTS TRANSACTION TO BE ACCRETIVE TO COMPANY'S NON-GAAP EARNINGS PER SHARE (EPS) IN 2018 AND BEYOND

BRIEF-NuVasive Inc reports Q3 GAAP earnings per share $0.64

* NuVasive Inc sees revenue and non-GAAP revenue of $1,030 million for fy 2017

BRIEF-NuVasive announces $100 million share repurchase program

* NuVasive Inc - intends to fund repurchases under share repurchase program from cash on hand, cash generated from operations

BRIEF-NuVasive receives expanded FDA 510(k) clearance For TLX Interbody System used in TLIF procedures

* NuVasive receives expanded FDA 510(k) clearance For TLX Interbody System used in TLIF procedures

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up